natgillin/translations-raw huggingface dataset:
Inactivated BTV 1 ....................................................................................................... 1.9 log10 pixels
Inaktivirani BTV 1 .................................................................................................... 1,9 log10piksela
Inactivated BTV 1 ...................................................................................................... 1.9 log10 pixels
Inaktivirani BTV 1 ...................................................................... 1,9 log10piksela
Inactivated BTV1 ..................................................................................................... 1.9 log10 pixels*
Inaktivirani BTV1 ................................................................................................... 1,9 log10piksela
Inactivated chimeric flavivirus strain YF-WN ≥ 492 AU Iscom-Matrix
Inaktivirani kimerni flavivirus, soj YF-WN ≥ 492 AU AU1 Iskom-Matrix
Inactivated chimeric flavivirus strain YF-WN ≥ 492 AU1
Inaktivirani kimerni flavivirus soj YF-WN ≥ 492 AU1
Inactivated chimeric flavivirus strain YF-WN ≥ 492 AU1 Iscom-Matrix containing:
Inaktivirani kimerni flavivirus soj YF-WN ≥ 492 AU1 Isokom – Matrix2 koji sadržava:
Inactivated Coxiella burnetii, strain Nine Mile > 72 QF Units*
Inaktivirana Coxiella burnetii, soj Nine Mile ≥72 QF jedinica
Inactivated Coxiella burnetii, strain Nine Mile > 72 QF Units/ml
Inaktivirana Coxiella burnetii, soj Nine Mile ≥72 QF jedinica / ml
Inactivated Coxiella burnetii, strain Nine Mile > 72 QF Units/ml
Inaktivirana Coxiella burnetii, soj Nine Mile ≥72 QF jedinica/ml
Inactivated Erysipelothrix rhusiopathiae, strain R32E11, .....................
Inaktivirani Erysipelothrix rhusiopathiae, soj R32E11 .................
Inactivated Erysipelothrix rhusiopathiae, strain R32E11, ......................
Inaktivirani Erysipelothrix rhusiopathiae, strain R32E11 ................
Inactivated Erysipelothrix rhusiopathiae, strain R32E11, .........................
Inaktivirani Erysipelothrix rhusiopathiae, strain R32E11 ................
Inactivated Erysipelothrix rhusiopathiae, strain R32E11, ELISA > 3.34 IE50%
Inaktivirani Erysipelothrix rhusiopathiae, soj R32E11 ELISA > 3,34
Inactivated feline calicivirus (FCV 431 and FCV G1 strains) antigens ..........................  2.0 ELISA U.
Inaktivirani antigen kalicivirusa mačaka (soj FCV 431 i FCV G1)................................  2,0 ELISA U.
Inactivated feline calicivirus (FCV 431 and FCV G1 strains) antigens ..........................  2.0 ELISA U.
Inaktivirani antigeni kalicivirus mačaka (soj FCV 431 i FCV G1) ................................ . 2,0 ELISA U.
Inactivated feline calicivirus (FCV 431 and FCV G1 strains) antigens ..........................  2.0 ELISA U. Attenuated Chlamydophila felis (905 strain) .....................................................................  103.0 EID502
Inaktivirani antigeni kalicivirusa mačaka (soj FCV 431 i FCV G1) .............................  2,0 ELISA U. Atenuirana Chlamydophila felis (soj 905) ........................................................................  103,.0 EID502
Inactivated feline calicivirus (FCV 431 and G1 strains) antigens ..................................  2.0 ELISA U.
Inaktivirani antigen kalicivirusa mačaka (soj FCV 431 i G1) ........................................  2,0 ELISA U.
Inactivated feline calicivirus (FCV 431 and G1 strains) antigens...................................  2.0 ELISA U. Attenuated Chlamydophila felis (905 strain) .....................................................................  103.0 EID502
Inaktivirani antigenikalicivirus mačaka (soj FCV 431 i G1) ..........................................  2,0 ELISA U. Atenuirana Chlamydophila felis (soj 905) ........................................................................  103,0 EID502
Inactivated foot-and-mouth disease antigen, at least 6 cattle PD50 per strain.
Inaktivirani antigen bolesti slinavke i šapa, najmanje 6 goveđih PD50 po soju
Inactivated foot-and-mouth disease antigen, at least 6 cattle PD50 per strain.
Inaktivirani antigen bolesti slinavke i šapa, najmanje 6 goveđih PD50 po soju.
Inactivated foot-and-mouth disease antigens are purified and do not contain sufficient amounts of non-structural proteins (NSP) to induce an antibody response following administration of a trivalent vaccine containing an amount of antigen corresponding with at least 15 PD50 per strain per dose of 2 ml.
Inaktivirani antigeni bolesti slinavke i šapa purificirani su i ne sadrže dovoljne količine nestrukturnih proteina (NSP) kako bi inducirali odgovor protutijela nakon primjene trivalentnog cjepiva s količinom antigena koja odgovara najmanje 15 PD50 po soju u dozi od 2 ml.
Inactivated foot-and-mouth disease antigens are purified and do not contain sufficient amounts of non-structural proteins (NSP) to induce an antibody response following administration of a trivalent vaccine containing an amount of antigen corresponding with at least 15 PD50 per strain per dose of 2 ml.
Inaktivirani antigeni bolesti slinavke i šapa purificirani su i ne sadrže dovoljne količine nestrukturnih proteina (NSP) kako bi inducirali odgovor protutijela nakon primjene trivalentnog cjepiva s količinom antigena koja odgovara najmanje 15 PD50 po soju, u dozi od 2 ml.
Inactivated FPV (RP 8.50–12.25); FCV (RP 1.26–2.40); FVR (RP 1.39–2.10); Chlam (RP 1.69–3.50); FeLV (RP 1.45–2.00).
Inaktivirani virusi panleukopenije mačaka (RP 8,50 – 12,25); mačji kalicivirusi (RP 1,26 – 2,40); virusi mačjeg rinotraheitisa (RP 1,39 – 2,10); Chlamydophila felis (RP 1,69 – 3,50); virusi mačje leukemije (RP 1,45 – 2,00)
Inactivated Leptospira strains:
Inaktivirani Leptospira sojevi:
Inactivated Leptospira strains:
Inaktivirani sojevi Leptospira :
Inactivated Leptospira strains:
Inaktivirani sojevi Leptospira:
Inactivated porcine circovirus type 2 (PCV2) .................................................  1.8 log10 ELISA Units
Inaktivirani cirkovirus svinja, tip 2 (PCV2) ................................................  1,8 log10 ELISA jedinica
Inactivated porcine circovirus type 2 (PCV2) .................................................  1.8 log10 ELISA.Units
Inaktivirani cirkovirus svinja, tip 2 (PCV2) ................................................  1,8 log10 ELISA jedinica
Inactivated porcine circovirus type 2 (PCV2) .................................................  1.8 log10 ELISA.Units
Inaktivirani cirkovirus svinja, tip 2 (PCV2) ................................................  1.8 log10 ELISA jedinica
Inactivated porcine parvovirus, strain NADL-2, .....................................................
Inaktivirani parvovirus svinja, soj NADL-2 ...........................................................
Inactivated porcine parvovirus, strain NADL-2, .....................................................
Inaktivirani parvovirus svinja, soj NADL-2 ............................................................
Inactivated porcine parvovirus, strain NADL-2, .......................................................
Inaktivirani parvovirus svinja, soj NADL-2 ..............................................................
Inactivated rabbit haemorrhagic disease type 2 virus (RHDV2), strain V-1037 ≥70% cELISA40
Inaktivirani virus hemoragijske bolesti kunića tipa 2 (RHDV2), soj V-1037 ≥70% cELISA40
Inactivated rabbit haemorrhagic disease type 2 virus (RHDV2), strain V-1037: ≥70% cELISA40*
Inaktivirani virus hemoragijske bolesti kunića tipa 2 (RHDV2) sojV-1037: ≥70% cELISA40
Inactivated rabbit haemorrhagic disease type 2 virus (RHDV2), strainV-1037 ≥70% cELISA40* (*) ≥70 % of vaccinated rabbits shall give cELISA antibody titres equal to or higher than 40.
Inaktivirani virus hemoragijske bolesti kunića tipa 2 (RHDV2), sojV-1037 ≥70% cELISA40* (*) ≥70 % cijepljenih kunića u testu cELISA imaju titar protutijela 40 ili viši.
Inactivated rabies virus, strain SAD Vnukovo-32 ≥ 2.0 IU***
Inaktivirani virus bjesnoće, soj SAD Vnukovo-32 ≥ 2,0 I.J.
Inactivated recombinant chimeric PCV type 1 containing the PCV type 2 ORF2 protein
Inaktivirani rekombinirani himerni cirkovirus svinja tip 1, koji sadrži ORF2 protein cirkovirusa svinja tipa 2
Inactivated recombinant chimeric porcine circovirus type 1containing the porcine circovirus type 2 ORF2 protein
Inaktivirani rekombinirani himerni cirkovirus svinja tip 1, koji sadrži ORF2 protein cirkovirusa svinja tipa 2
Inactivated RHDV2, strain V-1037: ≥70% cELISA40
Inaktivirani RHDV2, soj V-1037: ≥70% cELISA40
Inactivated Schmallenberg virus (RP ≥ 1/dose)
Inaktivirani virus Schmallenberg (RP ≥ 1/doza)
Inactivated type 2 poliovirus 8 DU
inaktivirani poliovirus tip 2, 8 DU
Inactivated type 3 poliovirus 32 DU
inaktivirani poliovirus tip 3 32 DU
Inactivated viral vaccine, to stimulate active immunity against bluetongue virus serotype 8.
Inaktivirana virusna vakcina, za poticanje aktivnog imuniteta protiv virusa plavog jezika serotipa 8.
Inactivated West Nile virus, strain VM-2 (1.0–2.2 RP).
Inaktivirani virus zapadnog Nila, soj VM-2 1,0 – 2,2 RP
Inactivated West Nile virus, strain VM-2 RP* 1.0–2.2
Inaktivirani virus zapadnog Nila, soj VM-2 RP* 1,0 – 2,2
Inactivated West Nile virus, strain VM-2.
Inaktivirani virus zapadnog Nila, soj VM-2.
Inactivated whole avian influenza virus antigen of H5N2 subtype (strain A/duck/Potsdam/1402/86), inducing an HI titre of ≥6.0 log2 as tested according to the potency test.
Inaktivirani antigen podtip H5N2 virusa ptičje influence (soj A/pačji/Potsdam/1402/86) koji inducira HI titar ≥ 6,0 log2, testirano prema potencijskom testu
Inactivated whole avian influenza virus antigen of H5N2 subtype (strain A/duck/Potsdam/1402/86), inducing an HI titre of ≥6.0 log2 as tested according to the potency test.
Inaktivirani antigen podtip H5N2 virusa ptičje influence (soj A/pačji/Potsdam/1402/86) koji inducira HI titar ≥ 6,0 log2, testirano prema potencijskom testu.
inadequate asthma control and in frequent need of a reliever inhaler. asthma exacerbations in the past requiring medical intervention.
neadekvatnom kontrolom astme i učestalom primjenom inhalatora za hitno simptomatsko liječenje egzacerbacijama astme u prošlosti koje su zahtijevale medicinsku intervenciju.
Inadequate dosing and/or discontinuation of anti-diabetic treatment may lead to hyperglycaemia and potentially to hyperosmolar coma.
Neodgovarajuće doziranje i/ili prekid terapije lijekovima za šećernu bolest može dovesti do hiperglikemije, a potencijalno i do hiperosmolarne kome.
Inadequate factor IX recovery p, *
neodgovarajući povrat faktora IX p,
inadequate food intake,
nedovoljan unos hrane
inadequate food intake,
nedovoljan unos hrane,
Inadequate response
Neadekvatan odgovor
Inadequate Response to Methotrexate
Nedovoljan odgovor na metotreksat
Inadequate Response to MTX
Nedovoljan odgovor na MTX
Inadequate Response to TNF Inhibitor
Nedovoljan odgovor na TNF-inhibitor
Inadequate therapeutic response*
neodgovarajući terapijski odgovor
Inadvertent administration of an 0.5 ml dose of IXIARO in children aged 1 to <3 years does not pose any safety concerns (section 5.1.).
Nehotična primjena doze od 0,5 ml cjepiva IXIARO kod djece u dobi od 1 do <3 godine ne predstavlja zabrinutost po pitanju sigurnosti (dio 5.1.).
Inadvertent intravascular injection could lead to thromboembolic event and disseminated intravascular coagulation (DIC), and there is also a risk of anaphylactic reaction (see Section 4.4).
Slučajna injekcija u krvnu žilu može uzrokovati tromboembolijski događaj i diseminiranu intravaskularnu koagulaciju (DIK), a postoji i rizik od anafilaktičke reakcije (vidjeti dio 4.4).
Inadvertent, unintentional, or unsupervised switching of immediate- or prolonged-release formulations of tacrolimus is unsafe.
Nepažljivo, nenamjerno ili nenadzirano mijenjanje farmaceutskih oblika takrolimusa s trenutnim oslobađanjem s farmaceuskim oblikom takrolimusa s produljenim oslobađanjem nije sigurno.
Inappropriate and excessive reaction to an allergen.
Neuobičajena ili burna reakcija na alergen.
inappropriate antidiuretic hormone secretion
neadekvatna sekrecija antidiuretskog hormona
Inappropriate antidiuretic hormone secretion*
neadekvatno izlučivanje antidiuretskog hormona
Inappropriate antidiuretic hormone secretion*
neodgovarajuće lučenje antidiuretskog hormona
Inappropriate antidiuretic hormone secretion*
neprimjereno lučenje antidiuretskog hormona
inappropriate antidiuretic hormone secretion1
dispneja, štucanje
inappropriate antidiuretic hormone secretion1
neadekvatno izlučivanje antidiuretskog hormona1
inappropriate antidiuretic hormone secretion1
neodgovarajuća sekrecija antidiuretskog hormona1
inappropriate antidiuretic hormone secretion1
neprimjereno lučenje antidiuretskog hormona1
inappropriate antidiuretic hormone secretionc, glucose urine present
neadekvatna sekrecija antidiuretskog hormonac, prisutnost glukoze u urinu
inappropriate secretion of a hormone that controls urine volume
neprimjereno lučenje hormona koji kontrolira volumen mokraće
inappropriate secretion of a hormone that controls urine volume, sugar in the urine
neodgovarajuće lučenje hormona koji kontrolira volumen mokraće, šećer u mokraći
Incidenc e rate per 100 patient- years*
Stopa incidencije na 100 bolesnik- godina
Incidence (%) of confirmed nocturnalc hypoglycaemia (n/Total N)
Incidencija (%) potvrđene noćnec hipoglikemije (n/ukupan N)
Incidence (%) of confirmedb hypoglycaemia (n/Total N)
Incidencija (%) potvrđeneb hipoglikemije (n/ukupan N)
Incidence (%) of severea hypoglycaemia (n/Total N)
Incidencija (%) teškea hipoglikemije (n/ukupan N)
Incidence at Baseline n (%)a
Incidencija na početku n (%)a
Incidence of adverse reactions from controlled clinical studies and post-marketing experience are:
Incidencija nuspojava iz kontroliranih kliničkih ispitivanja i iskustva stečenih nakon stavljanja lijeka u promet je:
Incidence of adverse reactions from controlled clinical studies and post-marketing experience are:
Incidencija nuspojava iz kontroliranih kliničkih studija i iskustva nakon stavljanja lijeka u promet je:
Incidence of adverse reactions with Fabrazyme treatment
Incidencija nuspojava kod liječenja lijekom Fabrazyme
Incidence of autograft
Incidencija presatka vlastite kože
Incidence of CNS adverse reactions such as dizziness may be higher after a loading dose.
Incidencija nuspojava SŽS-a kao što je omaglica može biti pojačana nakon udarme doze.
Incidence of fractures.
Incidencija prijeloma.
Incidence of hypoglycaemia at endpoint
Incidencija hipoglikemije na kraju ispitivanja
Incidence of individual adverse reactions following the first infusion was: fever (17.1%), myalgia (7.8%), flu-like symptoms (6.7%), arthralgia (4.8%) and headache (5.1%).
Incidencija pojedinih nuspojava nakon prve infuzije hila je: vrućica (17,1%), mialgija (7,8%), simptomi nalik gripi (6,7%), artralgija (4,8%) i glavobolja (5,1%).
Incidence of laboratory abnormalities in TT01 and TT02 (n=80 patients)
Incidencija laboratorijskih abnormalnosti u ispitivanjima TT01 i TT02 (n=80 pacijenata)
Incidence of PN (%)
Incidencija PN (%)
Incidence of rash and severe cutaneous reactions
Incidenciju osipa i teških kožnih reakcija
Incidence of total strokes and intracranial haemorrhage
Incidencija ukupnih moždanih udara i intrakranijalnog krvarenja
Incidence per 1,000 women in placebo arm over 5 years
Pojavnost na 1000 žena u placebo skupini tijekom 5 godina
Incidence per 100 person-years (95% CI)
Incidencija na 100 osoba-godina (95% CI)
Incidence rate of PHN per 1,000 person years
Stopa incidencije PHN-a na 1000 osoba godina
Incidence rate of zoster per 1,000 person years
Stopa incidencije herpes zostera na 1000 osoba godina
Incidence rate per 100 patient- years*
Stopa incidencije na 100 bolesnik- godina
Incidences (%)
Incidencija (%)
Incidences (%)
Incidencije (%)
Incidences of bleeding events in patients receiving the recommended regimen in the treatment of DVT or PE and aged <65 years, 65-75 and >75 years were 3.0 %, 4.5 % and 6.5 %, respectively.
Incidencija krvarenja u bolesnika koji su primali preporučene doze za liječenje DVT ili PE bila je 3% u dobnoj skupini <65 godina, 4,5% u bolesnika starih 65-75 godina, te 6,5% u starijih od 75 godina.
Incision site haemorrhage
Krvarenje na mjestu incizije
Incision site haemorrhage Vascular graft occlusion Wound
krvarenje na mjestu incizije okluzija vaskularnog presatka
Incision site infection
Infekcija na mjestu reza
INCIVO acts against the virus that causes hepatitis C infection and is used to treat chronic hepatitis C infection in adult patients (aged 18–65 years) in combination with peginterferon alfa and ribavirin.
INCIVO djeluje protiv virusa koji je uzročnik infekcije hepatitisa C i primjenjuje se za liječenje kronične infekcije hepatitisa C u odraslih bolesnika u kombinaciji s peginterferonom alfa i ribavirinom (u dobi od 18 do 65 godina).
INCIVO contains a substance called telaprevir and belongs to a group of medicines called ‘NS3-4A protease inhibitors’.
INCIVO sadrži tvar koja se zove telaprevir i pripada skupini lijekova koji se nazivaju ”inhibitori NS3-4A proteaze”.
INCIVO contains sodium
INCIVO sadrži natrij
INCIVO had no effects on fertility or fecundity when evaluated in rats.
INCIVO nije imao učinaka na plodnost ni oplodnju kada se ispitivao u štakora.
INCIVO has not been studied in patients with severe hepatic impairment (Child-Pugh C, score ≥ 10) or decompensated liver disease (ascites, portal hypertensive bleeding, encephalopathy, and/or jaundice other than Gilbert’s Syndrome) and is not recommended in these populations.
INCIVO nije ispitivan u bolesnika s teškim oštećenjem funkcije jetre (Child-Pugh C, indeks ≥ 10) ili s dekompenziranom bolešću (ascites, krvarenje uslijed portalne hipertenzije, encefalopatija, i/ili žutica tipa različitog od Gilbertovog sindroma) jetre te se ne preporučuje u ovoj populaciji bolesnika.
INCIVO in combination with peginterferon alfa and ribavirin was evaluated in 74 HCV-1 infected, post-liver transplant patients without cirrhosis receiving either tacrolimus or cyclosporine A. At the initiation of INCIVO treatment, doses of co-administered tacrolimus or cyclosporine A need to be markedly reduced, including a prolongation in the dosing interval for tacrolimus, in order to maintain therapeutic plasma concentrations of the immunosuppressant.
INCIVO je bio procijenjen u kombinaciji s peginterferonom alfa i ribavirinom u 74 bolesnika s HCV-1 infekcijom nakon transplantacije jetre bez ciroze koji su dobivali ili takrolimus ili ciklosporin A. Na početku liječenja INCIVOM, potrebno je znatno smanjiti doze istodobno primijenjenog takrolimusa ili ciklosporina A, uključujući produljenje intervala doziranja za takrolimus, radi održavanja terapijske koncentracije imunosupresiva u plazmi.
INCIVO in combination with peginterferon and ribavirin is not recommended in patients with platelets < 90,000/mm3 and/or albumin < 3.3 g/dl.
INCIVO u kombinaciji s peginterferonom i ribavirinom se ne preporučuje u bolesnika s trombocitima < 90.000/mm3 i/ili albuminom < 3,3 g/dl.
INCIVO is available in packs containing 1 bottle (total of 42 film-coated tablets) or 4 bottles (total of 168 film-coated tablets).
INCIVO je dostupan u pakiranjima s 1 bočicom (ukupno 42 filmom obložene tablete) ili 4 bočice (ukupno 168 filmom obloženih tableta).
INCIVO is not for use in children or adolescents, because it has not been sufficiently studied in patients under 18 years of age.
INCIVO nije namijenjen za primjenu u djece i adolescenata zbog toga što nije dovoljno ispitan u bolesnika mlađih od 18 godina,
INCIVO is not recommended in patients with moderate to severe hepatic impairment (Child-Pugh B or C, score ≥ 7) or decompensated liver disease (ascites, portal hypertensive bleeding, encephalopathy, and/or jaundice other than Gilbert’s Syndrome, see section 4.4).
INCIVO se ne preporučuje u bolesnika s umjerenim do teškim oštećenjem funkcije jetre (Child-Pugh B ili C, indeks ≥ 7) ili dekompenziranom bolešću jetre (ascites, krvarenje uslijed portalne hipertenzije, encefalopatija i/ili žutica tipa različitog od Gilbertovog sindroma, vidjeti dio 4.4).
INCIVO must be used in combination with peginterferon alfa and ribavirin.
INCIVO se mora uzimati u kombinaciji s peginterferonom alfa i ribavirinom.
INCIVO must not be administered concurrently with Class Ia or III antiarrhythmics, except for intravenous lidocaine.
INCIVO se ne smije primjenjivati istodobno s antiaritmicima skupine Ia ili III, osim s intravenskim lidokainom.
INCIVO must not be restarted if discontinued by your doctor.
Ne smijete ponovno početi uzimati INCIVO ako Vam je liječnik prekinuo primjenu tog lijeka.
INCIVO must not be taken alone and must be taken in combination with peginterferon alfa and ribavirin to be sure your treatment works.
Kako bi liječenje bilo djelotvorno, INCIVO se ne smije uzimati samostalno, nego se mora uzimati u kombinaciji s peginterferonom alfa i ribavirinom.
INCIVO treatment completed
Završeno liječenje INCIVOM
INCIVO, 1,125 mg (three 375 mg film-coated tablets) should be taken orally twice daily (b.i.d.) with food.
INCIVO treba uzimati u dozi od 1125 mg (tri filmom obložene tablete od 375 mg) peroralno dva puta na dan (b.i.d.) uz obrok.
INCIVO, in combination with peginterferon alfa and ribavirin, is indicated for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease (including cirrhosis):
INCIVO je indiciran u kombinaciji s peginterferonom alfa i ribavirinom za liječenje odraslih bolesnika s kroničnim hepatitisom C genotipa 1 i kompenziranom bolešću jetre (uključujući cirozu):
INCIVO.
INCIVOM.
Incline Therapeutics Europe Ltd 21 St. Thomas Street
Incline Therapeutics Europe Ltd 21 St.
Included in the pack
Uključeno u pakiranje
Included in the pack: a vial of Pegasys solution for injection
U pakiranju se nalazi: bočica s Pegasys otopinom za injekciju
Included in these studies were in total 402 subjects with BRAF V600E and 49 subjects with BRAF V600K mutation.
U ova ispitivanja je ukupno uključeno 402 ispitanika s BRAF V600E i 49 ispitanika s BRAF V600K mutacijom.
Included in this total were 1,262 patients (618 in the apixaban group) of age 75 or older, 1,004 patients (499 in the apixaban group) with low body weight (≤ 60 kg), 1,495 patients (743 in the apixaban group) with BMI ≥ 33 kg/m2, and 415 patients (203 in the apixaban group) with moderate renal impairment.
U taj broj ulaze 1262 bolesnika (618 u skupini koja je uzimala apiksaban) u dobi od 75 ili više godina, 1004 bolesnika (499 u skupini koja je uzimala apiksaban) male tjelesne težine (≤ 60 kg), 1495 bolesnika (743 u skupini koja je uzimala apiksaban) s BMI vrijednošću ≥ 33 kg/m2 i 415 bolesnika (203 u skupini koja je uzimala apiksaban) s umjerenim oštećenjem bubrežne funkcije.
Included patients who had ≥ 50 copies/mL in the Week 48 or 96 window; patients who discontinued early due to lack or loss of efficacy; patients who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a viral value of ≥ 50 copies/mL.
Obuhvatilo bolesnike koji su imali ≥ 50 kopija/ml u okviru 48. ili 96. tjedna; bolesnike koji su rano prekinuli liječenje ispitivanim lijekom zbog nedostatka ili gubitka djelotvornosti; bolesnike koji su prekinuli liječenje iz drugih razloga, a ne zbog štetnih događaja, smrti ili nedostatka ili gubitka djelotvornosti i koji su u vrijeme prekida liječenja imali virusnu vrijednost ≥ 50 kopija/ml.
Included patients who had ≥ 50 copies/mL in the Week 48 or 96 window; patients who discontinued early due to lack or loss of efficacy; patients who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a viral value of ≥ 50 copies/mL.
Obuhvatilo bolesnike koji su imali ≥ 50 kopija/ml u okviru 48. ili 96. tjedna; bolesnike koji su rano prestali primati ispitivani lijek zbog nedostatka ili gubitka djelotvornosti; bolesnike koji su prekinuli liječenje iz razloga koji nisu posljedica štetnog dogaĎaja, smrti ili nedostatka ili gubitka djelotvornosti i koji su u vrijeme prekida liječenja imali virusnu vrijednost ≥ 50 kopija/ml.
Includes 15% of subjects with previous history of HPV disease/infection
Uključuje 15% ispitanica s prethodnom HPV bolesti/infekcijom